Key Points
- California’s restrictions on kratom and 7-OH products have increased the importance of understanding what newer replacement products actually contain.
- Botanical blends can contain conventional herbal ingredients, concentrated plant extracts, proprietary alkaloids, or undisclosed psychoactive substances.
- Kava, kanna, blue lotus, akuamma, and other botanicals are pharmacologically different from 7-OH and are not established treatments for opioid withdrawal.
- Synthetic and semi-synthetic compounds such as mitragynine pseudoindoxyl, MGM-15, MGM-16, and experimental SR-series opioids should not be confused with traditional herbal supplements.
- Product names, including proprietary 7-OH alternatives, do not establish their ingredients, safety, legal status, or ability to treat dependence.
- How Phoenix Rising Helps: Phoenix Rising Recovery offers medically supervised detox and individualized addiction treatment in Palm Desert for people dealing with kratom, opioid-active products, and other substances.
What happens when a product someone depends on suddenly disappears from store shelves?
For some people, the answer is withdrawal. For others, it means looking for something else that promises similar effects without the same ingredients or regulatory restrictions.
That is one reason conversations about botanical blends and 7-OH alternatives deserve attention in California. The state has taken enforcement action against kratom and concentrated 7-hydroxymitragynine products, but consumers can still encounter unfamiliar supplements, extracts, and compounds marketed as substitutes.
Some are traditional botanicals with their own pharmacology. Others are proprietary formulations whose ingredients require careful verification. A separate group consists of powerful synthetic or semi-synthetic opioids that should never be mistaken for ordinary herbal supplements.
Understanding which category a product belongs to is far more useful than relying on a claim that it is natural, legal, or 7-OH-free.
Why Are Consumers Searching for Botanical Alternatives to 7-OH?
On January 16, 2026, the California Department of Public Health reinforced its position that kratom and 7-OH products are unlawful to manufacture or sell for consumption in California.
State officials warned that these products are sometimes marketed as solutions for pain, mood symptoms, or opioid withdrawal despite lacking FDA approval for those purposes.
When products become harder to obtain, someone who has developed physical dependence may face an immediate problem. They might experience insomnia, anxiety, gastrointestinal symptoms, restlessness, or cravings when they can no longer maintain their previous pattern of use.
A replacement product can seem like the simplest solution, particularly when a seller promises similar effects.
But changing substances does not necessarily eliminate physical dependence. If the replacement activates the same opioid receptors, or contains another undisclosed opioid, the underlying problem may remain.
This issue also appears in Phoenix Rising Recovery’s examination of Mitraxidine as a marketed 7-OH alternative.
What Are Botanical Blends?
The term botanical blend generally describes a product containing one or more plant-derived ingredients.
However, the term does not identify a specific pharmacological category.
One product might contain several familiar herbs. Another may combine concentrated extracts with proprietary ingredients. A third could be marketed using botanical terminology even though testing identifies a powerful chemically modified substance.
Consumers may encounter formulations promoted for relaxation, energy, mood, pain relief, or focus.
Those different intended effects matter because there is no single safety profile that applies to everything called a botanical blend.
Botanical Products Versus Synthetic Opioid Alternatives
| Product category | Examples | Important distinction |
|---|---|---|
| Traditional botanicals | Kava, kanna, blue lotus, Cat’s Claw | Plant-derived substances with differing effects and safety concerns |
| Other plant-based alternatives | Akuamma, corydalis, wild lettuce, Mitragyna hirsuta, Mitragyna javanica | Limited evidence for treating opioid withdrawal |
| Commercial proprietary blends | Mitraxidine, Acend, Tempo, Mit-OH, and similar marketed products | Individual formulas and claims require verification |
| Products associated with adulteration warnings | Certain Buzzers, Homiez, and Cat’s Claw-labeled products | Authorities have identified or suspected undisclosed opioid-active ingredients in specific products |
| Concentrated kratom derivatives | Enhanced 7-OH preparations | Different exposure from ordinary kratom leaf |
| Modified kratom-related opioids | Mitragynine pseudoindoxyl, MGM-15, MGM-16 | Potent opioid activity and significant regulatory concerns |
| Experimental synthetic opioids | SR-17018, SR-15099, SHR9352 | Laboratory-developed compounds, not herbal substitutes |
These categories are not interchangeable. A product’s inclusion in the same online discussion does not mean it contains the same chemicals or presents the same risks.
Kava, Kanna, and Blue Lotus: Are They Real 7-OH Alternatives?
These botanicals sometimes appear in conversations about relaxation, mood, and alternatives to concentrated kratom products.
They are not chemically equivalent to 7-OH.
Kava
Kava comes from Piper methysticum, a plant traditionally used in parts of the Pacific.
Its active compounds, known as kavalactones, can produce relaxing and sedating effects. Some consumers use kava beverages or extracts as alternatives to alcohol or other substances.
However, kava can cause adverse effects and interact with sedating medications. The National Institutes of Health also identifies concerns involving rare but potentially serious liver injury.
Ordinary kava is not an opioid and has not been established as an effective medical treatment for 7-OH withdrawal.
Kanna
Kanna, generally associated with Sceletium tortuosum, is a South African plant marketed in extracts and mood-related supplements.
Its alkaloids have been studied for activity involving serotonin-related pathways. This differs from the opioid-receptor activity associated with 7-OH.
Clinical evidence remains limited, particularly for highly concentrated commercial products.
Kanna should not be considered a proven replacement for opioid-withdrawal medication, and potential interactions with serotonergic medications warrant caution.
Blue Lotus
Blue lotus, often identified as Nymphaea caerulea, is sold in teas, extracts, and other products promoted for relaxation.
Its psychoactive properties have attracted online interest, but human safety and effectiveness data are limited.
Commercial extracts may differ substantially from traditional botanical preparations. Consumers should not assume that a concentrated product has the same composition or effects as the original plant.
Akuamma, Corydalis, Wild Lettuce, and Other Plant-Based Substitutes
Other botanicals appear in discussions about pain management or alternatives to kratom.
Akuamma: Derived from Picralima nitida, akuamma contains alkaloids that have attracted interest for potential pain-related effects. However, it lacks sufficient clinical evidence supporting its use for opioid withdrawal or addiction treatment.
Corydalis: Certain species contain compounds such as tetrahydropalmatine (L-THP), which have been investigated for neurological and pain-related activity. Research interest does not establish safety for self-directed withdrawal treatment.
Wild lettuce: Sometimes advertised as wild opium, wild lettuce is a separate botanical substance. Its nickname should not be interpreted as evidence that it functions like an established opioid medication.
Mitragyna hirsuta and Mitragyna javanica: These plants are related to kratom but have different alkaloid profiles. Their botanical relationship does not establish that they can prevent withdrawal from concentrated 7-OH.
Some products marketed as alternatives also contain combinations of ordinary botanicals, including kava and kratom. Brand-name beverages and shots, such as certain Feel Free or Kanva formulations, should be evaluated by their actual ingredient lists rather than assumed to contain a single standardized substance.
None of these botanical categories has an established, FDA-approved protocol for treating dependence on concentrated 7-OH.
What About Buzzers, Thizziez, Homiez, and Cat’s Claw Blends?
A different concern involves products promoted with botanical names but investigated for potentially undisclosed opioid compounds.
In July 2026, the Utah Poison Control Center warned about certain products marketed as Cat’s Claw or kava blends, including Buzzers and Homiez.
Officials reported serious overdoses and suspected that some investigated products contained kratom-related opioid compounds that were not disclosed on their labels.
An October 2026 follow-up described laboratory identification of mitragynine pseudoindoxyl and MGM-15 in certain products.
Names such as Thizziez and other proprietary products may also appear in online discussions about replacement blends. However, a product name alone is not evidence that a particular formulation contains an undisclosed opioid.
This distinction is important. It would be inaccurate to describe every kava supplement, Cat’s Claw product, or similarly named proprietary blend as adulterated.
The danger lies in specific products whose composition does not match their presentation.
San Francisco provided a particularly serious example in October 2026 when officials reported a fatal MGM-15 overdose involving a product sold as Script Botanicals × Maui Labs and labeled as Cat’s Claw.
That case demonstrates why a botanical name is not sufficient proof of a product’s ingredients.
Mitraxidine, Acend, Tempo, Mit-OH, and Other Commercial Alternatives
Another category consists of products promoted directly or indirectly as alternatives to concentrated 7-OH.
Consumers may encounter names such as Mitraxidine, Acend, Tempo, Mit-OH, KLAZ, Nuke, and other newly marketed formulations.
These are commercial names or product families, not a single recognized chemical class. Their compositions, marketing claims, and availability may change over time.
A manufacturer might promote a product as free of 7-OH, but that statement alone does not answer whether it contains another opioid-active alkaloid, how consistently it is manufactured, or whether it has been evaluated for repeated use.
There is also no reliable medical basis for assuming that one proprietary blend can be substituted for a particular amount of 7-OH.
Phoenix Rising has covered this distinction in greater detail in Mitraxidine and 7-OH: When Switching Products Isn’t Enough.
Pseudoindoxyl, MGM-15, MGM-16, and Smax Pseudo-DHM
These substances require a different level of concern because they involve compounds with significant opioid activity.
Mitragynine pseudoindoxyl (MGPI) is chemically related to kratom alkaloids and has been identified in some concentrated consumer products.
MGM-15, also called dihydro-7-hydroxymitragynine, is a chemically modified derivative associated with serious opioid toxicity and documented fatalities.
MGM-16 is another modified compound with strong opioid activity in preclinical research. Its human safety profile remains inadequately characterized.
Smax Pseudo-DHM is a product name appearing in investigations involving concentrated kratom-related compounds. Reported product information has identified pseudoindoxyl, MGM-15, and 7-OH among its listed ingredients. Product identification and toxicology findings must be evaluated separately before assigning responsibility for any particular death.
Federal regulators temporarily placed MGPI, MGM-15, and MGM-16 into Schedule I in August 2026. Subsequent October notices addressed continued controls and a revised proposed approach to concentrated 7-OH and MGPI.
These are not ordinary herbs. They should not be presented as harmless alternatives simply because some compounds are chemically related to a plant.
What About 9-OH, 13-OH, MGM-9, and New Alkaloid Names?
Online discussions sometimes include unfamiliar names such as 9-OH, 13-OH, MGM-9, and other numbered alkaloid designations.
Consumers should be particularly careful with terminology that has no consistently documented chemical identity, standardized product specification, or adequate human toxicology research.
A name appearing in a forum or advertisement does not establish that the substance is a well-characterized chemical, that a commercial product contains the claimed compound, or that it has a known safety profile.
These terms should be distinguished from substances such as MGM-15, for which investigators have documented specific analytical findings and public-health consequences.
The number attached to a product name does not indicate a predictable strength, dose, or safety advantage.
SR-17018, SR-15099, and SHR9352 Are Not Botanical Products
Experimental synthetic opioids have also entered discussions involving 7-OH alternatives and withdrawal.
SR-17018, sometimes called SR-17, has been studied in laboratory and animal models for its activity at mu-opioid receptors.
SR-15099, sometimes marketed or discussed as SR 2.0, is a related research compound. SHR9352 is another experimental opioid with a separate research history.
These substances have generated scientific interest because of their receptor-signaling properties. However, preclinical findings cannot establish that they are safe or effective treatments for human opioid dependence.
SR-17018 was temporarily scheduled federally in August 2026. SR-15099 and SHR9352 do not have established FDA-approved roles in opioid withdrawal treatment.
People should not attempt to manage dependence with experimental opioids purchased as research chemicals.
Are Botanical Blends Safer Than Kratom or 7-OH?
That question cannot be answered for botanical blends as a whole.
A conventional herbal supplement, a multi-ingredient relaxation beverage, and an adulterated tablet containing MGM-15 have fundamentally different risks.
Safety depends on factors including:
- The actual active ingredients and their concentrations
- Whether the ingredients have been independently verified
- How frequently and for how long the substance is used
- Concurrent medications, alcohol, and other drugs
- Existing physical dependence or medical conditions
In California, consumers should also understand that retail availability does not establish regulatory approval or lawful sale.
The FDA has not approved 7-OH products as treatments for pain, anxiety, depression, or opioid withdrawal.
What Happens When Someone Replaces One Product With Another?
Switching products can change the substance someone consumes without resolving the reasons they began using it.
A person might initially use 7-OH for pain, then rely on it to avoid withdrawal, and eventually begin using another product for the same purpose.
Even when the replacement has a different chemical composition, the person may remain caught in a cycle of cravings, substance-seeking behavior, and difficulty functioning without it.
There is an important distinction between using another unregulated product and receiving medically supervised treatment.
Evidence-based treatment for opioid use disorder can include medications such as buprenorphine, methadone, or naltrexone when clinically appropriate. Decisions involving concentrated kratom derivatives or unfamiliar products require individualized assessment because product-specific clinical evidence is limited.
For people struggling with these substances, a professional withdrawal evaluation can be more useful than experimenting with another blend.
Botanical Blend and 7-OH Addiction Treatment in Southern California
Phoenix Rising Recovery provides addiction treatment in Palm Desert for people from Riverside County, San Bernardino County, Los Angeles County, San Diego County, and the surrounding Coachella Valley.
Our team can assess substance use patterns, withdrawal concerns, co-occurring mental health needs, and the appropriate level of treatment.
Medical detox may be appropriate for individuals experiencing significant opioid-like withdrawal. Residential treatment and continued outpatient care can address the behavioral, emotional, and practical challenges of sustained recovery.
The goal is not simply to find another product that prevents withdrawal temporarily. It is to build a plan that addresses dependence and helps someone regain control over their life.
Contact Phoenix Rising Recovery at 866-985-1103 to discuss treatment options in Southern California.
Frequently Asked Questions
Are botanical blends legal in California?
Legality depends on the ingredients and how the product is manufactured and marketed. California prohibits the manufacture or sale of kratom and 7-OH products for consumption, while separate laws apply to other substances.
Can kava or kanna stop 7-OH withdrawal?
Neither has been established through adequate clinical evidence as an effective treatment for 7-OH withdrawal. They have different pharmacological properties and may introduce additional risks.
Are all Cat’s Claw products dangerous?
No. Traditional Cat’s Claw is a separate botanical supplement. Public-health warnings concern specific products marketed using botanical names that have been found or suspected to contain powerful opioid-active compounds.
Is MGM-15 safer than 7-OH?
There is no reliable clinical evidence establishing MGM-15 as a safer substitute. It is a highly potent opioid-active compound associated with fatal overdose.
Can someone become dependent on a product labeled 7-OH-free?
Potentially, yes. A product may contain other substances capable of producing physical dependence. Its actual ingredients and effects matter more than a marketing claim.
Sources and References
California Department of Public Health. (2026, January 16). CDPH warns retailers and public about the dangers of kratom-derived products and 7-OH. https://www.cdph.ca.gov/Programs/OPA/Pages/NR26-005.aspx
National Center for Complementary and Integrative Health. (n.d.). Kava: Usefulness and safety. National Institutes of Health. https://www.nccih.nih.gov/health/kava
National Center for Complementary and Integrative Health. (n.d.). Kratom. National Institutes of Health. https://www.nccih.nih.gov/health/kratom
U.S. Department of Health and Human Services. (2026, October 9). HHS recommends science-based thresholds to target dangerous enhanced kratom products. https://www.hhs.gov/press-room/hhs-recommends-thresholds-enhanced-kratom-products-7-oh-mgpi.html
U.S. Food and Drug Administration. (2026). Hiding in plain sight: 7-OH products. https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products
Utah Poison Control Center. (2026, July 22; updated October 5). Adulterated Cat’s Claw and kava products may cause opioid overdose. University of Utah Health. https://poisoncontrol.utah.edu/news/2026/07/adulterated-cats-claw-and-kava-products-may-cause-opioid-overdose
Utah Poison Control Center. (2026, October 5). Utah health officials warn of fatal overdoses involving illegal “cat’s claw” and kratom product. University of Utah Health. https://poisoncontrol.utah.edu/news/2026/10/utah-health-officials-warn-of-fatal-overdoses-involving-illegal-cats-claw-and-kratom